Kisqali® Tablets for HR+ HER2− Breast Cancer

Kisqali® is a prescription CDK4/6 inhibitor for certain breast cancers. It is used with endocrine therapy to treat HR-positive, HER2-negative advanced or metastatic disease. This page helps you understand how the treatment works, who it may suit, and how to access it through our service.

What Kisqali Is and How It Works

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing. This medicine blocks cyclin-dependent kinases 4 and 6, which can slow cell division in HR-positive tumors. It is typically combined with an aromatase inhibitor or fulvestrant. Ships from Canada to US is available through our service. We also outline the Kisqali price without insurance so you can plan your budget with your care team.

The treatment is taken by mouth and works systemically. It may help delay progression when added to endocrine therapy. Your clinician monitors blood counts, liver tests, and heart rhythm as recommended on the official label.

Who It’s For

Kisqali used for advanced or metastatic HR-positive, HER2-negative breast cancer in adults. It is prescribed with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant after disease progression on endocrine therapy. For those who are premenopausal or perimenopausal, ovarian suppression is usually added to the combination as recommended in labeling.

People who should avoid this class include those with known hypersensitivity to components, and those where risks outweigh benefits based on serious baseline heart rhythm issues or severe, uncontrolled liver problems. It is not recommended during pregnancy or breastfeeding. Effective contraception is advised during therapy and for the period after treatment specified on the label.

Dosage and Usage

The standard regimen is a once-daily dose taken for 21 days, followed by 7 days off to complete a 28-day cycle. Swallow tablets whole with water. You may take it with or without food, at about the same time each day. Do not chew, crush, or split the tablets.

If you vomit after taking a dose, do not take an extra dose that day. Avoid grapefruit or grapefruit juice because of interaction potential. Strong CYP3A inhibitors or inducers can change blood levels of the drug; your clinician may select alternatives when possible. Clinicians may adjust, interrupt, or temporarily stop therapy based on lab results, such as low neutrophil counts or elevated liver enzymes, consistent with the official prescribing information.

The commonly used daily amount is 600 mg at the start of therapy, but your prescriber will set the exact plan and may modify it if needed. Always follow the label and your clinician’s instructions.

Strengths and Forms

The product is supplied as film-coated oral tablets, commonly available in 200 mg strength. Pack sizes and co-packs can vary by market. Availability may vary by pharmacy partner and region.

Missed Dose and Timing

If you miss a dose, take the next scheduled dose at the usual time the following day. Do not take two doses at once to make up for a missed dose. Keep a consistent daily routine during the 21 days on therapy, followed by 7 days off, unless your prescriber adjusts your schedule.

Storage and Travel Basics

Store tablets in the original container, protected from moisture, and out of reach of children and pets. Keep them at standard room conditions per labeling. Do not use tablets that are damaged or show signs of deterioration.

For travel, pack enough supply for the entire trip, plus a small buffer approved by your clinician. Keep the medicine in your carry-on with the prescription label. A copy of your prescription can help with security or customs. If your trip crosses time zones, maintain the same interval between doses and ask your clinician for planning tips.

Benefits

This therapy targets cell-cycle signaling that drives tumor growth in HR-positive disease. It works with endocrine therapy to enhance treatment effectiveness compared with endocrine therapy alone in many patients, according to clinical evidence reflected in labeling. Oral dosing supports at-home use. The cyclic schedule gives defined treatment and rest periods, with monitoring to support safe use.

Side Effects and Safety

Kisqali side effects can vary. Common effects include changes in blood counts, digestive upset, and fatigue. Your care team will monitor labs regularly and may adjust therapy as needed.

• Low white blood cells, especially neutropenia
• Nausea, vomiting, diarrhea, or constipation
• Fatigue and decreased appetite
• Headache or dizziness
• Abnormal liver tests
• Alopecia or hair thinning
• Infections, including upper respiratory infections

Serious risks can include QT interval prolongation, severe neutropenia, hepatotoxicity, and rare interstitial lung disease or pneumonitis. Seek urgent care for symptoms like chest pain, fainting, severe shortness of breath, yellowing of the skin or eyes, or high fever. This medicine can harm an unborn baby. Discuss contraception and pregnancy testing per label recommendations.

Drug Interactions and Cautions

Kisqali interactions involve CYP3A. Strong CYP3A inhibitors (such as certain antifungals or antibiotics) may raise levels; strong inducers (such as some seizure medicines) may lower levels. Your clinician may choose alternatives or adjust therapy under the label’s guidance.

Avoid grapefruit or Seville oranges. Use caution with other medicines that prolong the QT interval, including some antiarrhythmics or macrolide antibiotics. Tell your clinician about all prescription drugs, over-the-counter products, vitamins, and herbal supplements, particularly St. John’s wort. Liver disease, electrolyte imbalances, or existing heart rhythm issues warrant additional monitoring.

What to Expect Over Time

During the first cycles, your team will check labs often. Many people settle into a routine after early monitoring. Some notice fatigue or mild stomach upset that may improve with supportive care. Kisqali hair loss is usually mild thinning and may be reversible after treatment is stopped.

Tumor response and disease control are assessed by imaging, tumor markers, and symptoms at intervals set by your clinician. Call your care team about new fevers, worsening fatigue, or unusual bruising. Keeping a medication journal can help you track patterns and prepare for appointments.

Compare With Alternatives

Other CDK4/6 inhibitors include palbociclib and abemaciclib. Some patients start on one agent and may switch based on tolerability, clinical factors, or prescriber preference. We offer Verzenio®, another option in this class. Your clinician will decide which partner endocrine therapy best fits your treatment plan.

Pricing and Access

We highlight Kisqali price and transparent options to help you estimate out-of-pocket amounts. You can review Canadian pricing with US delivery from Canada and talk with your care team. For occasional offers, visit our Promotions page. Final outlays depend on prescription details and your payment method.

Savings CTA: Explore ways to lower costs by discussing assistance routes with your clinician and by comparing Canadian rates through our service.

Pricing CTA: View current pricing, upload your prescription, and we will verify it with your prescriber before dispensing.

Availability and Substitutions

Supply can vary. There is no approved generic in many markets at this time, and Ribociclib brand name products are typically dispensed. If it is unavailable, your prescriber may recommend a suitable alternative or endocrine partner based on your history and label guidance. We do not promise restock dates; we will keep you informed about options.

Patient Suitability and Cost-Saving Tips

This therapy may suit adults with HR-positive, HER2-negative advanced breast cancer when combined with appropriate endocrine partners. It may not suit individuals with significant uncontrolled heart rhythm problems, severe hepatic impairment without close oversight, or those who are pregnant or breastfeeding. Always confirm with your clinician.

• Multi-month refills: Ask about 60- or 90-day supplies when appropriate.
• Refill reminders: Set calendar alerts to avoid gaps between cycles.
• Budget planning: Discuss the monthly cost of therapy with your care team.
• Coordination: Align blood tests and visits with cycle starts for convenience.
• Documentation: Keep a current medication list for emergency care.

For information on endocrine partners, see articles on Exemestane 25 Mg Tablets, Fulvestrant Injection Uses, and What Is Anastrozole. For additional targeted options in oncology, you can also review our guide: Afinitor Uses. We use encrypted checkout to protect your information.

Questions to Ask Your Clinician

• Is this CDK4/6 inhibitor right for my tumor profile?
• Which endocrine partner will I take with it, and why?
• How often will I need blood tests and EKG monitoring?
• What signs should prompt me to call the clinic right away?
• Which medicines, foods, or supplements should I avoid?
• If I develop low blood counts, how might my plan change?
• How can I coordinate travel with my dosing cycles?

Authoritative Sources

Novartis Kisqali Product Site

FDA DailyMed Prescribing Information

Health Canada Drug Product Database

Explore Related Topics

Learn more about the condition and category: Breast Cancer, Cancer, and country of origin details: Canada. For side effect support, see Handle Exemestane Side Effects for coping strategies you can discuss with your clinician.

Ready to move forward? You can start your request today for US shipping from Canada with prompt, express shipping. A valid prescription is required. This information is educational and does not replace your clinician’s advice.